SEC 13F Intelligence

Managers / Q1 2026

Catalio Capital Management, LP

CIK 0001958125 · 512 W. 22ND STREET, 5TH FLOOR, NEW YORK, NY, 10011 · 410-989-6168

Reported Value
$479M
Q1 2026
Positions
41
Filings on Record
6
2019–present window
Filed
May 15, 2026
original filing

Summary

Catalio Capital Management, LP reported $479M in U.S.-listed holdings across 41 positions for Q1 2026.

Its largest position, DNTH, represents 9.8% of the portfolio.

Compared with Q4 2025, the fund opened 10 new positions and exited 14.

Portfolio Metrics

Turnover
+34.9%
vs prior filed quarter
Top-10 Concentration
+54.5%
share of reported value
Largest Position
+9.8%
Dianthus Therapeutics
New / Exited
10 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’24: $457MQ4 ’24Q1 ’25: $411MQ1 ’25Q2 ’25: $477MQ2 ’25Q3 ’25: $541MQ3 ’25Q4 ’25: $566MQ4 ’25Q1 ’26: $479MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 87.4%Other: 8.4%ADR: 4.2%
  • Common Stock · 87.4% · $418M
  • Other · 8.4% · $40M
  • ADR · 4.2% · $20M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BBIOBRIDGEBIO PHARMA INCNEW+432.0K432.0K+$32M$32M
DFTXDEFINIUM THERAPEUTICS INCNEW+1.04M1.04M+$20M$20M
INCYINCYTE CORPNEW+182.1K182.1K+$17M$17M
CRVSCORVUS PHARMACEUTICALS INCNEW+891.9K891.9K+$13M$13M
MANEVERADERMICS INCNEW+173.6K173.6K+$11M$11M
4XC1KALVISTA PHARMACEUTICALS INCNEW+426.6K426.6K+$9M$9M
NEWAMSTERDAM PHARMA COMPANYNEW+83.6K83.6K+$3M$3M
TYRATYRA BIOSCIENCES INCNEW+67.3K67.3K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

41 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DNTHDIANTHUS THERAPEUTICS INChistory →COM9.82%$47M560.3K
2BBIOBRIDGEBIO PHARMA INChistory →COM6.70%$32M432.0K
3ASCENDIS PHARMA A/SSPONSORED ADR6.17%$30M129.1K
4BMYBRISTOL-MYERS SQUIBB COhistory →COM5.33%$26M420.7K
5SNDXSYNDAX PHARMACEUTICALS INChistory →COM5.09%$24M1.04M
6GILDGILEAD SCIENCES INChistory →COM4.77%$23M163.9K
7430TERNS PHARMACEUTICALS INChistory →COM4.50%$22M409.0K
8DFTXDEFINIUM THERAPEUTICS INChistory →COM SHS4.10%$20M1.04M
9SLNOEURSOLENO THERAPEUTICS INChistory →COM4.04%$19M577.8K
10BSXBOSTON SCIENTIFIC CORPhistory →COM3.92%$19M299.3K
11RAREULTRAGENYX PHARMACEUTICAL INhistory →COM3.72%$18M850.8K
12INCYINCYTE CORPhistory →COM3.58%$17M182.1K
13CYTKCYTOKINETICS INChistory →COM NEW2.97%$14M215.5K
14NTRANATERA INChistory →COM2.96%$14M70.9K
15CRVSCORVUS PHARMACEUTICALS INChistory →COM2.73%$13M891.9K
16GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS2.57%$12M255.4K
17MLYSMINERALYS THERAPEUTICS INChistory →COM2.48%$12M439.0K
18EWEDWARDS LIFESCIENCES CORPhistory →COM2.42%$12M144.6K
19MANEVERADERMICS INChistory →COMMON STOCK2.29%$11M173.6K
20ADPTADAPTIVE BIOTECHNOLOGIES CORhistory →COM2.10%$10M722.8K
21HTFLHEARTFLOW INChistory →COM2.05%$10M403.6K
224XC1KALVISTA PHARMACEUTICALS INChistory →COM1.79%$9M426.6K
23UNIQURE NVSHS1.68%$8M491.1K
24IRONDISC MEDICINE INChistory →COM1.64%$8M123.0K
25SEPNSEPTERNA INChistory →COM1.48%$7M294.4K
26ABVXABIVAX SAhistory →SPONSORED ADS1.10%$5M47.2K
27DYNDYNE THERAPEUTICS INChistory →COM1.07%$5M283.0K
28ELDNELEDON PHARMACEUTICALS INChistory →COM1.06%$5M1.64M
29KPTIKARYOPHARM THERAPEUTICS INChistory →COM NEW1.04%$5M897.7K
30SUPNSUPERNUS PHARMACEUTICALSCOM0.67%$3M62.0K
31TARAPROTARA THERAPEUTICS INCCOM STK0.63%$3M580.0K
32PHATPHATHOM PHARMACEUTICALS INCCOM0.58%$3M247.8K
33NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES0.56%$3M83.6K
34TYRATYRA BIOSCIENCES INCCOM0.54%$3M67.3K
35IMCRIMMUNOCORE HLDGS PLCADS0.53%$3M84.4K
36GUTSFRACTYL HEALTH INCCOM0.53%$3M5.49M
37HYPRHYPERFINE INCCOM CL A0.30%$1M1.32M
38MGXMETAGENOMI THERAPEUTICS INCCOM0.15%$708,851529.0K
39ATAIATAIBECKLEY INCCOM SHS0.15%$696,877196.9K
40FTHSENSEI BIOTHERAPEUTICS INCCOM NEW0.10%$463,91114.7K
41OMOUTSET MED INCCOM NEW0.09%$454,191118.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$479M41May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$566M45Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$541M38Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$477M40Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$411M37May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$457M33Feb 14, 202513F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.